α-Synuclein-IN-22

α-Synuclein-IN-22 (2ed) (30 μM; 72 h) potently inhibits the aggregation of recombinant α-synuclein in vitro, with an aggregation inhibition rate (AIR) of 91.1%^[1].
α-Synuclein-IN-22 (0-100 μM; 72 h) inhibits the aggregation of recombinant α-synuclein in a dose-dependent manner, with an IC₅₀ of 2.7 μM^[1].
α-Synuclein-IN-22 (30 μM; 72 h) stabilizes the random coil secondary structure of recombinant α-synuclein monomers and inhibits the formation of β-sheet-rich α-synuclein aggregates^[1].
α-Synuclein-IN-22 (30 μM; up to 96 h) inhibits the aggregation kinetics of recombinant α-synuclein at a concentration of 30 μM^[1].
α-Synuclein-IN-22 (30 μM; 88 h) reduces the formation of large, interconnected recombinant α-synuclein fibrils and generates shorter fibrils with lower abundance^[1].
α-Synuclein-IN-22 (30 μM; added at 21 h, 33 h, or 45 h, with incubation continued to a total of 88 h) effectively dissociates recombinant α-synuclein aggregates and inhibits their re-aggregation; it exhibits the highest potency when added at a concentration of 30 μM during the lag phase (with an AIR of 81.6% at 88 h)^[1].
α-Synuclein-IN-22 binds to the aggregation-prone α-synuclein fragment 58-79 (3Q28) with a binding energy of -10.06 kcal/mol, and this binding is mediated by hydrogen bonds, hydrophobic interactions, and π-stacking^[1].
α-Synuclein-IN-22 (10 μM; 48 h) inhibits the formation of α-synuclein (α-Syn) inclusions in H4 glioma cells transfected with △155/SNCAIP, reducing the proportion of inclusion-positive cells by 1.7-fold^[1].
α-Synuclein-IN-22 (1-1000 μM; 24 h) exhibits low cytotoxicity in H4 glioma cells and SH-SY5Y neuroblastoma cells^[1].
α-Synuclein-IN-22 (10 μM; 30 min) scavenges reactive oxygen species (ROS) in H4 glioma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.